MCID: IDP011
MIFTS: 61

Idiopathic Interstitial Pneumonia

Categories: Respiratory diseases

Aliases & Classifications for Idiopathic Interstitial Pneumonia

MalaCards integrated aliases for Idiopathic Interstitial Pneumonia:

Name: Idiopathic Interstitial Pneumonia 12 15
Idiopathic Interstitial Pneumonias 38 74
Pulmonary Fibrosis 45 74
Idiopathic Interstitial Pneumonia, Not Otherwise Specified 74
Diffuse Idiopathic Pulmonary Fibrosis 12
Idiopathic Fibrosing Alveolitis 12
Hamman-Rich Syndrome 74
Ipf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2797
KEGG 38 H01716
MeSH 45 D011658
SNOMED-CT 69 45157009

Summaries for Idiopathic Interstitial Pneumonia

Disease Ontology : 12 A pneumonia located in the lung parenchyma of unknown cause.

MalaCards based summary : Idiopathic Interstitial Pneumonia, also known as idiopathic interstitial pneumonias, is related to nonspecific interstitial pneumonia and desquamative interstitial pneumonia, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Idiopathic Interstitial Pneumonia is SFTPC (Surfactant Protein C), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Sodium Citrate and Bosentan have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and bone, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 77 Idiopathic interstitial pneumonia (IIP), or noninfectious pneumonia are a class of diffuse lung... more...

Related Diseases for Idiopathic Interstitial Pneumonia

Diseases related to Idiopathic Interstitial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 418)
# Related Disease Score Top Affiliating Genes
1 nonspecific interstitial pneumonia 33.6 CCL2 IFNG IL13 SFTPC TGFB1
2 desquamative interstitial pneumonia 33.2 MUC5B SFTPC
3 acute interstitial pneumonia 32.5 SFTPA1 SFTPA2 SFTPD
4 interstitial lung disease 31.8 CCL2 CXCL8 EDN1 IFNG IL4 MUC5B
5 pneumonia 31.1 CCL2 CXCL8 ELANE IL13 MUC5B SFTPC
6 extrinsic allergic alveolitis 31.0 CCL2 CXCL8 SFTPD
7 acute respiratory distress syndrome 30.7 CXCL8 ELANE SFTPC SFTPD
8 pulmonary fibrosis, idiopathic 30.6 CCL2 CCN2 CXCL8 EDN1 ELANE IFNG
9 silicosis 30.5 CCL2 CXCL8 SFTPD TGFB1
10 pneumoconiosis 30.5 CCL2 CXCL8 MUC5B TGFB1
11 pulmonary sarcoidosis 30.4 CCL2 ICAM1 IFNG SFTPD
12 connective tissue disease 30.4 CCN2 EDN1 IFNG SFTPD
13 arthritis 30.3 CCL2 CXCL8 IFNG TGFB1
14 sarcoidosis 1 30.3 IFNG IL13 PTPRC
15 sleep apnea 30.3 CXCL8 EDN1 ICAM1
16 pulmonary alveolar proteinosis 30.3 CCL2 SFTPC SFTPD
17 respiratory failure 30.2 CXCL8 ELANE SFTPC SFTPD
18 systemic scleroderma 30.2 CCN2 EDN1 IFNG SFTPD TGFB1
19 pulmonary emphysema 30.2 ELANE SFTPC SFTPD
20 severe acute respiratory syndrome 30.1 CCL2 CXCL8 IFNG
21 allergic asthma 30.1 IFNG IL13 IL4
22 schistosomiasis 30.1 IFNG IL13 IL4
23 mycoplasma pneumoniae pneumonia 30.0 IFNG IL13 IL4
24 pulmonary edema 30.0 CXCL8 EDN1 ICAM1
25 bronchiolitis 30.0 CXCL8 IFNG IL13 IL4 MUC5B
26 pulmonary eosinophilia 30.0 IL13 IL4 SFTPD
27 adult respiratory distress syndrome 30.0 CXCL8 ELANE SERPINE1 SFTPC
28 esophagitis 30.0 CXCL8 IL13 TGFB1
29 rapidly progressive glomerulonephritis 30.0 ELANE ICAM1 TGFB1
30 otitis media 29.9 CXCL8 IL4 MUC5B
31 surfactant dysfunction 29.8 SFTPA1 SFTPC
32 vascular disease 29.8 CCL2 EDN1 ELANE SERPINE1 VEGFA
33 arteries, anomalies of 29.7 CCL2 EDN1 ICAM1 SERPINE1 VEGFA
34 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.7 CXCR4 IFNG IL4
35 contact dermatitis 29.6 CXCL8 ICAM1 IFNG IL4
36 pulmonary disease, chronic obstructive 29.6 CCL2 CXCL8 ELANE IL13 SFTPD TGFB1
37 pleurisy 29.6 CCL2 CXCL8 ICAM1 IFNG
38 kidney disease 29.4 CCL2 CCN2 EDN1 SERPINE1 TGFB1
39 systemic lupus erythematosus 29.4 CCL2 ELANE ICAM1 IFNG IL4 TGFB1
40 lung disease 29.3 CCL2 CXCL8 EDN1 ELANE IL13 MUC5B
41 rheumatoid arthritis 29.3 CCL2 CXCL8 ICAM1 IFNG IL4 TGFB1
42 vasculitis 29.3 CCL2 ELANE ICAM1
43 pulmonary fibrosis 29.3 CCL2 CCN2 EDN1 IL13 MUC5B SFTPA1
44 heart disease 29.0 CXCL8 EDN1 ICAM1 SERPINE1 VEGFA
45 asthma 28.9 CCL2 CXCL8 CXCR4 EDN1 ELANE ICAM1
46 malaria 28.8 CCL2 CXCL8 EDN1 ICAM1 IFNG IL13
47 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 12.8
48 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 12.7
49 pulmonary fibrosis and/or bone marrow failure, telomere-related, 4 12.6
50 pulmonary fibrosis and/or bone marrow failure, telomere-related, 3 12.6

Comorbidity relations with Idiopathic Interstitial Pneumonia via Phenotypic Disease Network (PDN): (show all 21)


Acute Cystitis Aortic Valve Disease 1
Bronchiectasis Bronchitis
Bronchopneumonia Chronic Myocardial Ischemia
Chronic Pulmonary Heart Disease Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Mitral Valve Disease Osteoporosis
Postinflammatory Pulmonary Fibrosis Protein-Energy Malnutrition
Pulmonary Hypertension, Primary, 1 Respiratory Failure
Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Idiopathic Interstitial Pneumonia:



Diseases related to Idiopathic Interstitial Pneumonia

Symptoms & Phenotypes for Idiopathic Interstitial Pneumonia

UMLS symptoms related to Idiopathic Interstitial Pneumonia:


hemoptysis, snoring, coughing

MGI Mouse Phenotypes related to Idiopathic Interstitial Pneumonia:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.37 CCN2 CXCR4 EDN1 GREM1 ICAM1 IFNG
2 homeostasis/metabolism MP:0005376 10.36 CCN2 CXCR4 EDN1 ELANE GREM1 ICAM1
3 immune system MP:0005387 10.31 CCL2 CXCR4 ELANE ICAM1 IFNG IL13
4 cellular MP:0005384 10.29 CCN2 CXCR4 GREM1 ICAM1 IFNG IL13
5 hematopoietic system MP:0005397 10.29 CXCR4 ELANE ICAM1 IFNG IL13 IL4
6 mortality/aging MP:0010768 10.25 CCN2 CXCR4 EDN1 ELANE GREM1 ICAM1
7 digestive/alimentary MP:0005381 10.22 CCN2 CXCR4 EDN1 ICAM1 IFNG IL13
8 endocrine/exocrine gland MP:0005379 10.21 CCN2 CXCR4 EDN1 ICAM1 IFNG IL13
9 craniofacial MP:0005382 10.08 CCN2 CXCR4 EDN1 IFNG IL4 TGFB1
10 integument MP:0010771 10.06 CCN2 CXCR4 ICAM1 IFNG IL13 IL4
11 liver/biliary system MP:0005370 9.91 CCN2 IFNG IL4 PTPRC SERPINE1 TGFB1
12 neoplasm MP:0002006 9.91 CXCR4 ELANE ICAM1 IFNG PTPRC SERPINE1
13 renal/urinary system MP:0005367 9.81 CXCR4 EDN1 GREM1 IFNG IL4 PTPRC
14 respiratory system MP:0005388 9.8 CCN2 CXCR4 GREM1 IFNG IL13 IL4
15 skeleton MP:0005390 9.32 CCN2 CXCR4 EDN1 GREM1 IFNG IL13

Drugs & Therapeutics for Idiopathic Interstitial Pneumonia

Drugs for Idiopathic Interstitial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68-04-2
2
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2 147536-97-8 104865
3
Pirfenidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53179-13-8 40632
4
Nintedanib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 656247-17-5 56843413
5
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 77-92-9 311
6 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2
7 Sildenafil Citrate Phase 4,Phase 3,Phase 2 171599-83-0
8 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Citrate Phase 4,Phase 3,Phase 2,Phase 1
10 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2
11 Endothelin Receptor Antagonists Phase 4,Phase 3,Phase 2
12 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
20
Iloprost Approved, Investigational Phase 2, Phase 3 78919-13-8 6443959
21
Acetylcysteine Approved, Investigational Phase 3,Phase 2,Phase 1 616-91-1 12035
22
Azathioprine Approved Phase 3,Phase 1,Phase 2,Not Applicable 446-86-6 2265
23
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
24
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
25
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
26
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
27
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
28
Methylprednisolone hemisuccinate Approved Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
29
Mycophenolic acid Approved Phase 3 24280-93-1 446541
30
rituximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
31
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
32
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2 135968-09-1
33
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
34
Losartan Approved Phase 2, Phase 3,Not Applicable 114798-26-4 3961
35
Angiotensin II Approved, Investigational Phase 2, Phase 3,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
37
Sulfamethoxazole Approved Phase 3 723-46-6 5329
38
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
39
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
40
Ambrisentan Approved, Investigational Phase 3 177036-94-1 6918493
41
Warfarin Approved Phase 3 81-81-2 54678486 6691
42
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
44
Prednisolone hemisuccinate Experimental Phase 3,Phase 1,Phase 2,Not Applicable 2920-86-7
45 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
46 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Platelet Aggregation Inhibitors Phase 2, Phase 3
48 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
49 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
50 Anticoagulants Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 362)
# Name Status NCT ID Phase Drugs
1 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
2 Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study Unknown status NCT00637065 Phase 4 Bosentan;Placebo
3 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
4 Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT02598193 Phase 4 Nintedanib;Pirfenidone
5 Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment Completed NCT02788474 Phase 4 nintedanib;placebo
6 Digital Auscultation Test - IPF Data Collection Completed NCT03503188 Phase 4
7 Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF Completed NCT02579603 Phase 4 Nintedanib;Pirfenidone
8 A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination Completed NCT02606877 Phase 4 nintedanib;pirfenidone
9 Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) Recruiting NCT03717012 Phase 4 Nintedanib
10 Management of Progressive Disease in Idiopathic Pulmonary Fibrosis Not yet recruiting NCT03939520 Phase 4 pirfenidone and nintedanib;pirfenidone or nintedanib
11 68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis Terminated NCT01321996 Phase 4
12 Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Withdrawn NCT00625079 Phase 4 sildenafil
13 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Withdrawn NCT00625469 Phase 4 bosentan
14 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
15 Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Unknown status NCT00439543 Phase 2, Phase 3 Iloprost inhalation
16 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00600028 Phase 3 Thalidomide;Placebo
17 Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 Completed NCT00631475 Phase 3 Bosentan
18 Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis Completed NCT02739165 Phase 3 ART-123;Placebo
19 Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01366209 Phase 3 Pirfenidone;Placebo
20 Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment Completed NCT02802345 Phase 3 Nintedanib;Placebo;Sildenafil
21 Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00071461 Phase 2, Phase 3 bosentan;Placebo
22 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287716 Phase 3 Pirfenidone;Placebo
23 Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287729 Phase 3 Pirfenidone;Placebo
24 BUILD 3: Bosentan Use in Interstitial Lung Disease Completed NCT00391443 Phase 3 Bosentan;Placebo
25 Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study Completed NCT00131274 Phase 2, Phase 3 Imatinib Mesylate (Gleevec)
26 Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01979952 Phase 3 Matching Placebo;Nintedanib
27 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis Completed NCT00517933 Phase 3 Sildenafil Citrate
28 Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00662038 Phase 3 pirfenidone
29 A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00047645 Phase 3 Interferon-gamma 1b
30 Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00639496 Phase 3 n-acetylcysteine;placebo
31 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients Completed NCT01335464 Phase 3 placebo;BIBF 1120
32 Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II Completed NCT01335477 Phase 3 placebo;BIBF 1120
33 Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization Completed NCT02584816 Phase 3
34 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Completed NCT00650091 Phase 3 N-acetylcysteine (NAC);Placebo
35 A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients Completed NCT01014442 Phase 3 mycophenolate mofetil
36 Rituximab in Rheumatoid Arthritis Lung Disease Completed NCT00578565 Phase 3 Rituximab
37 A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis Completed NCT02597933 Phase 3 Nintedanib;Placebo
38 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
39 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection Completed NCT00105183 Phase 3
40 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3 Bosentan
41 A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care Recruiting NCT03733444 Phase 3 GLPG1690;Placebo
42 A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care Recruiting NCT03711162 Phase 3 GLPG1690;Placebo
43 Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Recruiting NCT02460588 Phase 3 Cyclophosphamide;Placebo;Corticosteroid (prednisolone)
44 Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea Recruiting NCT03018756 Phase 3 Fentanyl Citrate;Placebo
45 CleanUP IPF for the Pulmonary Trials Cooperative Recruiting NCT02759120 Phase 3 Antimicrobial therapy: Co-trimoxazole or Doxycycline
46 Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). Active, not recruiting NCT03208933 Phase 3 Pirfenidone
47 Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis Active, not recruiting NCT01619085 Phase 3 BIBF 1120
48 Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Active, not recruiting NCT02999178 Phase 3 Nintedanib;Placebo
49 Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis Not yet recruiting NCT03955146 Phase 3 Pamrevlumab;Placebo
50 Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis Not yet recruiting NCT03068234 Phase 2, Phase 3 Pirfenidone;Placebo oral capsule;Steroids

Search NIH Clinical Center for Idiopathic Interstitial Pneumonia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: pulmonary fibrosis

Genetic Tests for Idiopathic Interstitial Pneumonia

Anatomical Context for Idiopathic Interstitial Pneumonia

MalaCards organs/tissues related to Idiopathic Interstitial Pneumonia:

42
Lung, Testes, Bone, Bone Marrow, Heart, Thyroid, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Idiopathic Interstitial Pneumonia:

20
The Lung Parenchyma Of Unknown Cause

Publications for Idiopathic Interstitial Pneumonia

Articles related to Idiopathic Interstitial Pneumonia:

(show top 50) (show all 309)
# Title Authors Year
1
Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias. ( 30913371 )
2019
2
Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia. ( 30928980 )
2019
3
Acute Exacerbation of Idiopathic Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma after Transcatheter Arterial Therapy Using Miriplatin. ( 30626817 )
2019
4
Cardiorespiratory adaptation during 6-Minute Walk Test in fibrotic idiopathic interstitial pneumonia patients who did or did not respond to pulmonary rehabilitation. ( 29904044 )
2019
5
The maximum dimension of the inferior vena cava is a significant predictor of postoperative mortality in lung cancer patients with idiopathic interstitial pneumonia. ( 30612207 )
2019
6
Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. ( 30665514 )
2019
7
POINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? Yes. ( 30732687 )
2019
8
COUNTERPOINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? No. ( 30732688 )
2019
9
Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name? ( 30765482 )
2019
10
Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name? ( 30765483 )
2019
11
The Role of Follow-up Evaluation in the Diagnostic Algorithm of Idiopathic Interstitial Pneumonia: A Retrospective Study. ( 31015608 )
2019
12
Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias. ( 30967948 )
2019
13
Continuous Neuromuscular Blockade and Mortality in Subjects With Exacerbation of Idiopathic Interstitial Pneumonias. ( 30154126 )
2019
14
Interstitial lung diseases in dogs and cats part I: The idiopathic interstitial pneumonias. ( 30606439 )
2019
15
Recombinant thrombomodulin for acute exacerbation in idiopathic interstitial pneumonias. ( 30835911 )
2019
16
Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion. ( 30880283 )
2019
17
Characterization of air flow and lung function in the pulmonary acinus by fluid-structure interaction in idiopathic interstitial pneumonias. ( 30921412 )
2019
18
Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias. ( 30972352 )
2019
19
Proposed method of histological separation between connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonias. ( 30395623 )
2018
20
Volume doubling time of lung cancer detected in idiopathic interstitial pneumonia: comparison with that in chronic obstructive pulmonary disease. ( 29038933 )
2018
21
Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-melanoma Differentiation-associated Gene-5 Antibody by Intensive Immunosuppressive Therapy. ( 29269659 )
2018
22
Cyclophosphamide in steroid refractory unclassifiable idiopathic interstitial pneumonia and interstitial pneumonia with autoimmune features (IPAF). ( 29496758 )
2018
23
A Serological Biomarker of Versican Degradation is Associated with Mortality Following Acute Exacerbations of Idiopathic Interstitial Pneumonia. ( 29728109 )
2018
24
Effects of pulmonary rehabilitation on daily life physical activity of fibrotic idiopathic interstitial pneumonia patients. ( 29900176 )
2018
25
Idiopathic Interstitial Pneumonia as a Possible Cause of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Case Report. ( 29901014 )
2018
26
Secondary pulmonary alveolar proteinosis predominant in the transplanted lung in patients with idiopathic interstitial pneumonia: an autopsy case. ( 29997992 )
2018
27
Diagnostic value of KL-6 in idiopathic interstitial pneumonia. ( 30233844 )
2018
28
Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias. ( 28758849 )
2018
29
Prevalence of Myositis-Specific Antibodies in Idiopathic Interstitial Pneumonias. ( 29532165 )
2018
30
Pathology and radiology correlation of idiopathic interstitial pneumonias. ( 29180253 )
2018
31
Unclassifiable idiopathic interstitial pneumonias: A never-ending story? ( 29325674 )
2018
32
Is idiopathic PPFE an established subset of idiopathic interstitial pneumonias? ( 29325678 )
2018
33
Clinico-radio-pathological characteristics of unclassifiable idiopathic interstitial pneumonias. ( 29325680 )
2018
34
The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias. ( 29434143 )
2018
35
Distinct Profiles of CD163-Positive Macrophages in Idiopathic Interstitial Pneumonias. ( 29507864 )
2018
36
Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate - Reply. ( 29527756 )
2018
37
Corticosteroids in acute exacerbations of idiopathic interstitial pneumonias: Time to debate. ( 29527763 )
2018
38
Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias. ( 29928060 )
2018
39
Update on Rare Idiopathic Interstitial Pneumonias and Rare Histologic Patterns. ( 30141991 )
2018
40
Idiopathic interstitial pneumonias: review of the latest American Thoracic Society/European Respiratory Society classification. ( 30369660 )
2018
41
Classification of idiopathic interstitial pneumonias. ( 30369675 )
2018
42
Respiratory bronchiolitis-associated interstitial lung disease - an unexpected form of idiopathic interstitial pneumonia in a young male. ( 28523329 )
2017
43
The pathological features of idiopathic interstitial pneumonia-associated pulmonary adenocarcinomas. ( 27757985 )
2017
44
Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? ( 27884593 )
2017
45
Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year. ( 28300570 )
2017
46
Impact of lymphocyte differential count > 15% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia. ( 28427425 )
2017
47
Baseline serum syndecan-4 predicts prognosis after the onset of acute exacerbation of idiopathic interstitial pneumonia. ( 28467516 )
2017
48
A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. ( 28838377 )
2017
49
Occupational and Environmental Risk Factors for Chronic Fibrosing idiopathic Interstitial Pneumonia in South Korea. ( 28938261 )
2017
50
Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. ( 29229096 )
2017

Variations for Idiopathic Interstitial Pneumonia

Expression for Idiopathic Interstitial Pneumonia

Search GEO for disease gene expression data for Idiopathic Interstitial Pneumonia.

Pathways for Idiopathic Interstitial Pneumonia

Pathways related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CCL2 CXCL8 ELANE ICAM1 IFNG IL13
2
Show member pathways
13.54 CCL2 CCN2 CXCL8 CXCR4 ICAM1 IFNG
3
Show member pathways
13.41 CCL2 CCN2 CXCL8 CXCR4 IL13 IL4
4
Show member pathways
13.4 CCL2 CXCL8 CXCR4 ICAM1 SERPINE1 TGFB1
5
Show member pathways
13.38 CCL2 CXCL8 ICAM1 IFNG IL13 IL4
6
Show member pathways
13.31 CCL2 CCN2 CXCL8 CXCR4 IL13 IL4
7
Show member pathways
13.1 CCL2 CXCL8 IFNG SERPINE1 SFTPA2 SFTPD
8
Show member pathways
12.97 CCL2 CXCL8 CXCR4 ICAM1 TGFB1 VEGFA
9 12.84 CXCL8 CXCR4 IFNG IL13 IL4 TGFB1
10
Show member pathways
12.76 CXCL8 CXCR4 ICAM1 IFNG IL13 IL4
11 12.59 CCL2 CXCR4 IFNG IL4 PTPRC
12
Show member pathways
12.55 IFNG IL4 PTPRC TGFB1
13
Show member pathways
12.43 CXCR4 IFNG IL13 IL4 PTPRC
14
Show member pathways
12.35 CCL2 ICAM1 IFNG IL4 SERPINE1
15
Show member pathways
12.35 CCL2 CXCL8 IFNG IL13 IL4 MUC5B
16
Show member pathways
12.28 CCN2 CXCL8 IFNG IL13 IL4 TGFB1
17 12.26 CCN2 GREM1 SERPINE1 TGFB1
18
Show member pathways
12.24 CXCL8 EDN1 MUC5B SERPINE1
19
Show member pathways
12.19 CXCL8 IFNG IL4 SFTPA1 SFTPD
20 12.1 CCL2 EDN1 ICAM1 IFNG VEGFA
21 11.98 CXCL8 IFNG SERPINE1 TGFB1
22 11.96 CCL2 CXCL8 ICAM1 IFNG IL4 TGFB1
23 11.94 EDN1 IFNG SERPINE1 VEGFA
24
Show member pathways
11.94 CCL2 CCN2 CXCL8 ICAM1 IFNG IL13
25
Show member pathways
11.9 SFTPA1 SFTPA2 SFTPC SFTPD
26 11.88 CXCL8 IFNG TGFB1
27
Show member pathways
11.86 CXCL8 ICAM1 TGFB1
28 11.84 CCL2 GREM1 TGFB1
29 11.82 IFNG IL13 IL4 PTPRC
30 11.82 CXCL8 ICAM1 IFNG IL13 IL4
31
Show member pathways
11.77 CXCL8 IFNG IL4
32 11.76 CXCL8 SFTPA1 SFTPA2
33 11.76 CCL2 CXCL8 ICAM1 IL13 IL4 TGFB1
34 11.75 IFNG PTPRC TGFB1
35 11.73 CCL2 IFNG IL13 IL4 TGFB1
36 11.71 CXCR4 EDN1 SERPINE1 VEGFA
37 11.69 CCL2 CXCL8 ICAM1 IFNG TGFB1 VEGFA
38
Show member pathways
11.68 CXCL8 ICAM1 IFNG VEGFA
39 11.64 IFNG SERPINE1 TGFB1
40 11.57 CXCL8 TGFB1 VEGFA
41 11.54 CCN2 ELANE ICAM1
42 11.54 CCL2 CXCL8 ICAM1 IL13 IL4
43
Show member pathways
11.52 SFTPA1 SFTPA2 SFTPD
44 11.52 IFNG IL13 IL4
45 11.52 CCL2 CXCL8 ICAM1 IFNG TGFB1
46 11.5 CXCL8 ICAM1 IFNG
47 11.5 CCL2 CXCL8 EDN1 ICAM1 SERPINE1 TGFB1
48
Show member pathways
11.48 SFTPA1 SFTPA2 SFTPC SFTPD
49 11.42 EDN1 SERPINE1 VEGFA
50 11.34 IFNG IL13 IL4

GO Terms for Idiopathic Interstitial Pneumonia

Cellular components related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 CCL2 CCN2 CXCL8 EDN1 ELANE GREM1
2 cell surface GO:0009986 9.87 CXCR4 ELANE GREM1 ICAM1 PTPRC TGFB1
3 collagen trimer GO:0005581 9.63 SFTPA1 SFTPA2 SFTPD
4 rough endoplasmic reticulum GO:0005791 9.61 SFTPA1 SFTPA2 SFTPD
5 platelet alpha granule lumen GO:0031093 9.58 SERPINE1 TGFB1 VEGFA
6 extracellular space GO:0005615 9.58 CCL2 CCN2 CXCL8 EDN1 ELANE GREM1
7 multivesicular body GO:0005771 9.54 SFTPA1 SFTPA2 SFTPD
8 clathrin-coated endocytic vesicle GO:0045334 9.46 SFTPA1 SFTPA2 SFTPC SFTPD
9 lamellar body GO:0042599 9.43 SFTPA1 SFTPA2 SFTPC

Biological processes related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 CCN2 IFNG IL13 IL4 TGFB1 VEGFA
2 cellular protein metabolic process GO:0044267 9.98 SFTPA1 SFTPA2 SFTPC SFTPD
3 positive regulation of protein phosphorylation GO:0001934 9.97 CCN2 IFNG TGFB1 VEGFA
4 negative regulation of gene expression GO:0010629 9.97 CCN2 EDN1 IFNG TGFB1 VEGFA
5 response to lipopolysaccharide GO:0032496 9.96 EDN1 ELANE ICAM1 IL13
6 cellular response to lipopolysaccharide GO:0071222 9.96 CCL2 CXCL8 ICAM1 SERPINE1
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 CCL2 CCN2 ICAM1 PTPRC TGFB1
8 positive regulation of angiogenesis GO:0045766 9.94 CXCL8 GREM1 SERPINE1 VEGFA
9 cellular response to tumor necrosis factor GO:0071356 9.9 CCL2 CXCL8 EDN1 ICAM1
10 calcium-mediated signaling GO:0019722 9.87 CXCL8 CXCR4 EDN1
11 neutrophil chemotaxis GO:0030593 9.86 CCL2 CXCL8 EDN1
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 EDN1 ELANE IL13
13 angiogenesis GO:0001525 9.85 CCL2 CCN2 CXCL8 GREM1 SERPINE1 VEGFA
14 positive regulation of cold-induced thermogenesis GO:0120162 9.84 CXCR4 IL13 IL4 VEGFA
15 T cell activation GO:0042110 9.83 IL4 PTPRC TGFB1
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 ICAM1 PTPRC TGFB1 VEGFA
17 response to hypoxia GO:0001666 9.83 CXCR4 EDN1 ICAM1 TGFB1 VEGFA
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 EDN1 ICAM1 IFNG
19 positive regulation of B cell proliferation GO:0030890 9.8 IL13 IL4 PTPRC
20 cellular response to interleukin-1 GO:0071347 9.8 CCL2 CXCL8 EDN1 ICAM1
21 cytokine-mediated signaling pathway GO:0019221 9.8 CCL2 CXCL8 ICAM1 IL13 IL4 TGFB1
22 positive regulation of phagocytosis GO:0050766 9.79 SFTPA1 SFTPA2 SFTPD
23 toll-like receptor signaling pathway GO:0002224 9.79 SFTPA1 SFTPA2 SFTPD
24 response to amino acid GO:0043200 9.77 CCN2 EDN1 ICAM1
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 IFNG IL13 IL4 VEGFA
26 positive regulation of protein complex assembly GO:0031334 9.72 IFNG TGFB1 VEGFA
27 positive regulation of MAP kinase activity GO:0043406 9.71 EDN1 ELANE TGFB1 VEGFA
28 induction of positive chemotaxis GO:0050930 9.7 CXCL8 VEGFA
29 positive regulation of cardiac muscle cell differentiation GO:2000727 9.7 GREM1 TGFB1
30 macrophage chemotaxis GO:0048246 9.7 CCL2 SFTPD
31 negative regulation of interleukin-17 production GO:0032700 9.69 IFNG TGFB1
32 PERK-mediated unfolded protein response GO:0036499 9.69 CCL2 CXCL8
33 positive regulation of isotype switching to IgG isotypes GO:0048304 9.68 IL4 PTPRC
34 acute inflammatory response to antigenic stimulus GO:0002438 9.68 ELANE ICAM1
35 negative regulation of interleukin-2 biosynthetic process GO:0045085 9.65 PTPRC SFTPD
36 response to salt GO:1902074 9.65 EDN1 TGFB1
37 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.65 GREM1 TGFB1 VEGFA
38 positive regulation of odontogenesis GO:0042482 9.63 EDN1 TGFB1
39 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.63 GREM1 VEGFA
40 negative regulation of endothelial cell apoptotic process GO:2000352 9.62 ICAM1 IL13 IL4 SERPINE1
41 negative regulation of complement-dependent cytotoxicity GO:1903660 9.58 IL13 IL4
42 surfactant homeostasis GO:0043129 9.46 SFTPA1 SFTPA2 SFTPD VEGFA
43 respiratory gaseous exchange GO:0007585 9.35 EDN1 SFTPA1 SFTPA2 SFTPC SFTPD
44 regulation of signaling receptor activity GO:0010469 9.32 CCL2 CCN2 CXCL8 EDN1 IFNG IL13
45 positive regulation of cell proliferation GO:0008284 10.08 CCN2 EDN1 GREM1 IFNG TGFB1 VEGFA
46 inflammatory response GO:0006954 10.06 CCL2 CXCL8 CXCR4 IL13 TGFB1
47 immune response GO:0006955 10.05 CCL2 CXCL8 CXCR4 IFNG IL13 IL4
48 cell surface receptor signaling pathway GO:0007166 10 CCL2 EDN1 IFNG PTPRC

Molecular functions related to Idiopathic Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 CCL2 CCN2 CXCL8 CXCR4 EDN1 ELANE
2 growth factor activity GO:0008083 9.67 CCN2 IL4 TGFB1 VEGFA
3 heparin binding GO:0008201 9.62 CCN2 ELANE PTPRC VEGFA
4 lipopolysaccharide binding GO:0001530 9.43 SFTPA1 SFTPA2 SFTPD
5 vascular endothelial growth factor receptor 2 binding GO:0043184 9.4 GREM1 VEGFA
6 monosaccharide binding GO:0048029 9.33 SFTPA1 SFTPA2 SFTPD
7 cytokine activity GO:0005125 9.28 CCL2 CXCL8 EDN1 GREM1 IFNG IL13

Sources for Idiopathic Interstitial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....